Last updated: March 14, 2026
What is NDC 00185-0211?
NDC 00185-0211 is the code assigned by the FDA to a specific drug product. This NDC code corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor primarily indicated for the treatment of various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
Market Size and Dynamics
Current Market Landscape
- Global Oncology Market: Estimated at $222 billion in 2022, predicted to reach $310 billion by 2027, at a CAGR of 6.8% (Frost & Sullivan, 2022).
- Checkpoint Inhibitors Segment: Accounts for roughly 25% of total oncology revenues, driven by drugs like Nivolumab and Pembrolizumab.
- Nivolumab Sales (2022): Estimated at $7.5 billion worldwide, marking a significant share within the immunotherapy market (IQVIA, 2022).
Key Competitive Landscape
| Drug |
Indications |
Estimated 2022 Sales |
Market Share (2022) |
Notable Competitors |
| Nivolumab (Opdivo) |
Melanoma, NSCLC, renal cell carcinoma |
$7.5 billion |
45% |
Pembrolizumab, Atezolizumab |
| Pembrolizumab (Keytruda) |
Multiple, including lung, melanoma |
$17.2 billion |
45% |
Nivolumab |
Key Drivers
- Expansion of indications for Nivolumab.
- Increasing approval for combination therapies.
- Rising prevalence of target cancers globally.
- Lobbying for expanded use in earlier treatment lines.
Price Dynamics and Projections
Current Pricing
- Average Wholesale Price (AWP): Approximately $13,500 per 40 mg vial (ASHP, 2023).
- Per Treatment Course: Cost ranges from $60,000 to $120,000 depending on dosing and indication.
- Reimbursement Landscapes: Varies across regions; in the U.S., Medicare and private insurers have negotiated discounts.
Price Trends (Last 5 Years)
- Prices for Nivolumab have remained relatively stable, with slight reductions attributable to competition and biosimilar advances in other drug classes.
- Introduction of biosimilar programs for immune checkpoint inhibitors remains limited, providing some price stabilization.
Future Price Projections (2023-2028)
| Year |
Estimated Price per Treatment Course |
Factors Influencing Price Changes |
| 2023 |
$60,000 - $120,000 |
Stable, with slight discounts due to volume negotiations |
| 2024 |
$58,000 - $115,000 |
Price optimization strategies, competitive pressures |
| 2025 |
$55,000 - $110,000 |
Increased biosimilar activity, new entrants reducing prices |
| 2026 |
$50,000 - $105,000 |
Biosimilars gain market share, competitive pricing pressure |
| 2027 |
$48,000 - $100,000 |
Biosimilar market expansion, cost-containment measures in payers' strategies |
Impact of Biosimilars
- Biosimilar development for Nivolumab is limited but forthcoming. Their entry could reduce price points by 20-30%, similar to other biologics.
- Regulatory pathways remain complex, delaying biosimilar market penetration.
Regulatory and Policy Environment
- FDA Approvals: Expanded indication approvals have contributed to revenue growth.
- Pricing Policies: US initiatives such as the Inflation Reduction Act may impact drug pricing strategies, potentially reducing net prices.
- Global Access: Pricing is lower in emerging markets, often 50-70% of US prices, driven by local pricing regulations and reimbursement policies.
Market Entry and Outlook
- Market growth remains solid, buoyed by expanding indications and combination therapies.
- Price competition is emerging but remains contained by brand strength and clinical efficacy.
- Biosimilars are expected to influence prices gradually from 2024 onward.
Key Takeaways
- Nivolumab remains a high-revenue immunotherapy with stable pricing.
- Market expansion through new indications and combination regimens sustains growth.
- Biosimilar competition may lead to a 20-30% reduction in prices over the next five years.
- Price reductions are also driven by payer strategies and regulatory policies.
FAQs
1. How does Nivolumab’s pricing compare to competitors?
Nivolumab’s per-course cost is comparable to Pembrolizumab, with slight variations based on dosing. Competition has limited recent price cuts, but biosimilars could alter this landscape.
2. What is the projected growth rate for Nivolumab sales?
Sales are expected to grow at a CAGR of approximately 8-10% through 2028, assuming continued indication expansion and combination use.
3. Will biosimilars significantly impact prices?
Yes. Biosimilars could reduce costs by 20-30%, but their market penetration depends on regulatory approvals and physician adoption.
4. Are there regional differences in pricing?
Yes. The US prices are the highest, with significant discounts in Europe and emerging markets. Price regulation policies can also vary widely.
5. What should investors consider regarding Nivolumab’s future?
Patents expire in key markets around 2028; early biosimilar entry, regulatory changes, and indication expansion will influence long-term profitability.
References
[1] Frost & Sullivan. (2022). Global Oncology Market Forecast.
[2] IQVIA. (2022). Top Selling Oncology Drugs.
[3] ASHP. (2023). Drug Pricing and Wholesale Acquisition Cost Data.
